Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation.
Adult
Aged
Aged, 80 and over
CD8-Positive T-Lymphocytes
/ immunology
Drug Resistance, Neoplasm
/ genetics
Exons
Female
Gastrointestinal Stromal Tumors
/ genetics
Gene Expression Profiling
Gene Ontology
Humans
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Middle Aged
Mutation
Receptor, Platelet-Derived Growth Factor alpha
/ genetics
Transcriptome
Tumor Microenvironment
/ genetics
D842V
GIST
IFN-γ signaling pathway
PDGFRA
checkpoint inhibitor
gastrointestinal stromal tumor
immunotherapy
tumor infiltrating lymphocytes
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
11
2019
accepted:
14
04
2020
entrez:
17
7
2020
pubmed:
17
7
2020
medline:
16
3
2021
Statut:
epublish
Résumé
Platelet Derived Growth Factor Receptor Alpha (PDGFRA) mutations occur in only about 5-7% of gastrointestinal stromal tumors (GIST), notably with alterations on exons 12/14/18. The most frequent PDGFRA mutation is the exon 18 D842V, which is correlated to specific clinico-pathological features, such as primary imatinib resistance and higher indolence. Here, we present a gene expression profile (GEP) comparison of D842V vs. PDGFRA with mutations other than D842V (non-D842V). GEP was followed by
Identifiants
pubmed: 32670260
doi: 10.3389/fimmu.2020.00851
pmc: PMC7326057
doi:
Substances chimiques
Receptor, Platelet-Derived Growth Factor alpha
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
851Informations de copyright
Copyright © 2020 Indio, Ravegnini, Astolfi, Urbini, Saponara, De Leo, Gruppioni, Tarantino, Angelini, Pession, Pantaleo and Nannini.
Références
J Clin Invest. 2019 Feb 14;129(5):1863-1877
pubmed: 30762585
J Clin Oncol. 2003 Dec 1;21(23):4342-9
pubmed: 14645423
Clin Cancer Res. 2017 Jan 15;23(2):454-465
pubmed: 27470968
Clin Cancer Res. 2012 Aug 15;18(16):4375-84
pubmed: 22745105
Science. 2003 Jan 31;299(5607):708-10
pubmed: 12522257
Eur J Cancer. 2004 Mar;40(5):689-95
pubmed: 15010069
J Clin Oncol. 2008 Nov 20;26(33):5360-7
pubmed: 18955451
Cancer Res Treat. 2016 Apr;48(2):546-52
pubmed: 26130666
Gastroenterology. 2003 Sep;125(3):660-7
pubmed: 12949711
Clin Cancer Res. 2014 Dec 1;20(23):6105-16
pubmed: 25294914
J Exp Med. 2013 Dec 16;210(13):2873-86
pubmed: 24323358
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
J Clin Oncol. 2008 Nov 20;26(33):5352-9
pubmed: 18955458
Nat Med. 2011 Aug 28;17(9):1094-100
pubmed: 21873989
Lab Invest. 2004 Jul;84(7):874-83
pubmed: 15146165
J Clin Oncol. 2005 Aug 10;23(23):5357-64
pubmed: 15928335
Cancer Immunol Res. 2018 Apr;6(4):434-447
pubmed: 29467128
Clin Cancer Res. 2019 Jan 15;25(2):609-618
pubmed: 30274985
Clin Cancer Res. 2012 Aug 15;18(16):4458-64
pubmed: 22718859
Oncoimmunology. 2019 Jun 4;8(9):e1617588
pubmed: 31428517
Am J Surg Pathol. 2015 Jul;39(7):922-30
pubmed: 25970686
Int J Mol Sci. 2018 Mar 04;19(3):
pubmed: 29510530